cas 37949-03-4|| where to buy 5,6,8,9-Tetrahydrobenzocyclohepten-7-one

製品名:5,6,8,9-Tetrahydrobenzocyclohepten-7-one

IUPAC Name:6,7,8,9-tetrahydro-5H-benzo[7]annulen-7-one

包装単位	有効在庫	価格（USD）
CM153084-10g	in stock	ŵŵǜȺ
CM153084-25g	in stock	ŵƦȺƎ

研究開発用専用.

問い合わせフォーム

化学物質名

CAS番号

数量*

要求仕様*
（アッセイ %、材料グレード等）

お名前*

連絡先Eメールアドレス*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 37949-03-4 regularly via the above email.

追記事項

Verification code*

refresh

: CAS番号:37949-03-4; 分子式:C11H12O; 融点:-; SMILESコード:O=C1CCC2=CC=CC=C2CC1; 密度:

: カタログ番号:CM153084; 分子量:160.22; 沸点:288.2±29.0°C at 760 mmHg; MDL番号:MFCD09867716; 保管方法:Store at room temperature.

: Benzenes; Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.

: Bemcentinib; Bemcentinib is a potentially first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC and severe respiratory infections. Extensive studies confirm the ability to combine bemcentinib with immune checkpoint inhibitors, chemotherapies and targeted therapies with the goal of improving a patient’s immune response and delaying the development of chemoresistance. Bemcentinib is currently being investigated in combination with immune checkpoint inhibition and chemotherapy in first line NSCLC patients harboring mutations in the STK11 gene, a known prognostic factor of poor response to existing therapies.